Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Antibody Oligonucleotide Conjugates

Eli Lilly HQ

Lilly claims another EU okay for Taltz

The IL-17 inhibitor can be used alone or in combination with methotrexate for PsA patients

- PMLiVE

Novartis bags new breakthrough status for Kisqali in breast cancer

The Swiss pharma group’s treatment will rival Lilly’s Verzenio and Pfizer’s Ibrance if approved

Sanofi reception

FDA approves Sanofi’s follow-on version of Lilly’s Humalog

French pharma firm hopes Admelog will make a significant commercial impact in 2018

Lilly appoints Philip Johnson to senior VP and treasurer

He currently serves as VP, investor relations at the pharma company

- PMLiVE

Lilly mulls divestment of its animal health operations

Pharma firm is due to make a final decision on Elanco in 2018

Lilly strengthens team with in-house promotions

And two senior leaders retire

Eli Lilly HQ

Lilly gets early US approval for Ibrance rival abemaciclib

The breast cancer treatment, marketed as Verzenio, will also compete with Novartis' Kisqali

Eli Lilly HQ

Lilly’s abemaciclib data leaves potential uncertain

MONARCH 3 trial showed similar results to Pfizer’s Ibrance and Novartis’ Kisqali

Eli Lilly HQ

Lilly planning early re-file for JAK inhibitor baricitinib

The arthritis treatment could reach US market a year earlier than expected

- PMLiVE

Novo’s semaglutide beats Lilly’s Trulicity in diabetes contest

Analysts predict the drug could be worth $8.7bn in the next five years

Eli Lilly HQ

Baricitinib delay casts a pall over Lilly’s results update

FDA requests further data that could keep the drug off the market for a couple of years

Eli Lilly HQ

Lilly pays Nektar $150m upfront for phase I autoimmune drug

Will add another $250m if candidate meets development objectives

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links